You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,745,485

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,745,485

Title:	Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
Abstract:	Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
Inventor(s):	Durden; Donald L. (Indianapolis, IN)
Assignee:	Indiana University Research and Technology Corporation (Indianapolis, IN)
Application Number:	12/342,848
Patent Claims:	1. A method for inhibiting metastasis of cancer cells in a patient in need thereof, comprising the administration of an effective amount of a PI-3 kinase inhibitor, said method further comprising assessing said patient for tumor invasion distant from site of origin following administration of said PI-3 kinase inhibitor. 2. A method as claimed in claim 1, wherein said PI-3 kinase inhibitor effectively blocks angiogenesis. 3. A method as claimed in claim 1, further comprising the administration of at least one additional chemotherapeutic agent. 4. A method as claimed in claim 3, wherein said at least one additional chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, asparaginase, vincristine, vinblastine, anthracyclines, microtubule disrupting agents, taxol, herceptin, and etoposides. 5. A method as claimed in claim 1, wherein said PI-kinase inhibitor is LY294002. 6. The method of claim 1, wherein said PI-3 kinase inhibitor is Wortmannin.

Details for Patent 7,745,485

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2020-05-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2020-05-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2020-05-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.